Browsing by Author "Alhalboosi, Jamal Khalid Ismael"

Now showing 1 - 2 of 2

Combined Treatment of Sinapic Acid and Ellagic Acid Attenuates Hyperglycemia in Streptozotocin-Induced Diabetic Rats
(Pergamon-elsevier Science Ltd, 2021) Altindag, Fikret; Ragbetli, Murat Cetin; Ozdek, Ugur; Koyun, Necat; Alhalboosi, Jamal Khalid Ismael; Elasan, Sadi
In the present study, we aimed to investigate the effect of individual and combined treatment of sinapic acid (SA) and ellagic acid (EA) in streptozotocin (STZ)-induced diabetic rats. Rats were divided into eight groups (n = 7): Normal Control, Diabetic Control, Diabetic + Sinapic Acid, Diabetic + Ellagic Acid, Diabetic + Sinapic Acid + Ellagic Acid, Sinapic Acid, Ellagic Acid and Sinapic Acid + Ellagic Acid. Diabetic groups were injected with a single dose of 50 mg/kg STZ intraperitoneally. Rats received 20 mg/kg/day SA and 50 mg/kg/day EA intragastrically for 28 days. The numerical density of immunopositive beta-cells and volume density of pancreatic islets were calculated. Additionally, glucose and insulin levels in serum, MDA, GSH, and CAT levels of pancreatic tissue were measured. While serum glucose levels increased, serum insulin levels decreased in STZ-induced diabetic rats. But these changes in glucose and insulin were restored by individual and combined treatments of SA and EA. Also, individual and combined treatments of SA and EA increased insulin expression of beta-cells in STZ-induced diabetic rats. Moreover, these compounds improved deteriorating oxidative stress parameters in STZ-induced diabetic rats. Our study indicates that SA and EA, especially their combined treatments, can be used as an antihyperglycemic agent in diabetes.
Syringic Acid Mitigates Scopolamine-Induced Cognitive Impairment by Regulating PSD-95 and GSK-3β and by Preventing Neurodegeneration in an Alzheimer-Like Rat Model
(Academic Press Inc Elsevier Science, 2026) Altindag, Fikret; Bayir, Mehmet Hafit; Alhalboosi, Jamal Khalid Ismael; Yildizhan, Kenan
Alzheimer's disease (AD) is a disorder characterized by progressive cognitive impairment. Syringic acid (SA) is a phenolic compound with many beneficial effects, such as antioxidant, anti-inflammatory, anti-diabetic, anticarcinogenic, and neuroprotective. Our study aimed to investigate the effects of SA (50 mg/kg/day) on scopolamine (SCO)-induced AD-like condition in rats. Immunohistochemical evaluation was performed using antibodies to postsynaptic density protein 95 (PSD-95), Glycogen synthase kinase-3 beta (GSK-3 beta), TNF-alpha, and caspase-3. The hippocampus was stained with Hematoxylin-Eosin, and the total number of hippocampal neurons and hippocampal volume were calculated using the stereological method. The Y-maze task behavioral test was performed. SCO decreased PSD-95 expression while increasing GSK-3 beta, TNF-alpha, and caspase-3 expression. SA treatment increased PSD-95 expression while decreasing GSK-3 beta, TNF-alpha, and caspase-3 expression. Compared to the control group, the number of hippocampal neurons was significantly decreased in the Alzheimer's group, but the number of neurons in the SA group was significantly higher than in the Alzheimer's group. Hippocampal volume was lower in the Alzheimer's group, although there was no statistical difference between the groups. SA also improved SCO-induced cognitive impairment. Our study findings suggest that SA may mitigate SCO-induced cognitive impairment in the AD rat model, modulating PSD-95 and GSK-3 beta and decreasing neuroinflammation and apoptosis.